Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Iambic Therapeutics, Inc.IAM · Entity 184417 | Chief Medical Officer | October 14, 2026 | October 14, 2026 |
| Zymeworks BC Inc.ZYME · Entity 12038 | Chief Medical Officer | November 10, 2022 | November 14, 2022 |
| Zymeworks Inc.ZYME · Entity 4458 | Chief Medical Officer | November 10, 2022 | December 23, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Iambic Therapeutics, Inc.
Report date October 14, 2026 · Filed October 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,459 |
Reported balance
Holding disclosure · report date 2026-10-14 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 40,459 |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.95 · Expires 2034-02-16 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-10-14 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: An option to purchase 215,992 shares was granted on February 16, 2024 and was exercised in part prior to the date on which the reporting person became subject to Section 16. Twenty-five percent of the shares subject to the option vested on January 31, 2025 and 1/48th of the shares vest monthly thereafter. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.73 · Expires 2036-03-03 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-10-14 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F2: The shares subject to the option vest in 48 equal monthly installments beginning on March 23, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: An option to purchase 215,992 shares was granted on February 16, 2024 and was exercised in part prior to the date on which the reporting person became subject to Section 16. Twenty-five percent of the shares subject to the option vested on January 31, 2025 and 1/48th of the shares vest monthly thereafter.
F2: The shares subject to the option vest in 48 equal monthly installments beginning on March 23, 2026.
Zymeworks BC Inc.
Report date November 10, 2022 · Filed November 14, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,449 |
Ending reported balance
After 2022-11-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-11-10 · Exercise / conversion · Acquired 5,885 · Balance 16,924 F1: Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on November 10, 2021. Row 2 · 2022-11-10 · Sale · Disposed 2,475 · Balance 14,449 F2: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs. Pursuant to the terms of the applicable RSU grant agreement (the "Grant Agreement"), effective on the grant date of the RSUs, the Reporting Person adopted a 10b5-1 plan pursuant to which the Reporting Person elected to sell shares to cover tax withholding obligations and other applicable fees in accordance with the terms of the Grant Agreement. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.09 to $8.10, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 11,772 |
Reported balance
After 2022-11-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-11-10 · Exercise / conversion · Disposed 5,885 · Balance 11,772 F4: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F5: The RSUs were granted on November 10, 2021 and vest in three equal annual instalments beginning on November 10, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on November 10, 2021.
F2: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs. Pursuant to the terms of the applicable RSU grant agreement (the "Grant Agreement"), effective on the grant date of the RSUs, the Reporting Person adopted a 10b5-1 plan pursuant to which the Reporting Person elected to sell shares to cover tax withholding obligations and other applicable fees in accordance with the terms of the Grant Agreement.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.09 to $8.10, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F4: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
F5: The RSUs were granted on November 10, 2021 and vest in three equal annual instalments beginning on November 10, 2022.
Zymeworks Inc.
Report date November 10, 2022 · Filed December 23, 2022 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,449 |
Last balance in matching sequence
After 2022-11-10 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2022-11-10 · Exercise / conversion · Acquired 5,885 · Balance 16,924 F1: Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on November 10, 2021. Row 2 · 2022-11-10 · Sale · Disposed 2,475 · Balance 14,449 F2: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs. Pursuant to the terms of the applicable RSU grant agreement (the "Grant Agreement"), effective on the grant date of the RSUs, the Reporting Person adopted a 10b5-1 plan pursuant to which the Reporting Person elected to sell shares to cover tax withholding obligations and other applicable fees in accordance with the terms of the Grant Agreement. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.09 to $8.10, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 11,772 |
Reported balance
After 2022-11-10 transaction · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · 2022-11-10 · Exercise / conversion · Disposed 5,885 · Balance 11,772 F4: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F5: The RSUs were granted on November 10, 2021 and vest in three equal annual instalments beginning on November 10, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on November 10, 2021.
F2: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs. Pursuant to the terms of the applicable RSU grant agreement (the "Grant Agreement"), effective on the grant date of the RSUs, the Reporting Person adopted a 10b5-1 plan pursuant to which the Reporting Person elected to sell shares to cover tax withholding obligations and other applicable fees in accordance with the terms of the Grant Agreement.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.09 to $8.10, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F4: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
F5: The RSUs were granted on November 10, 2021 and vest in three equal annual instalments beginning on November 10, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 10, 2022 Filed Nov 14, 2022 21:41 UTC | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionRestricted Stock Unit · Derivative | 5,885 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-035813 · doc4.xml · derivative · entry 3 Josephson Neil · CIK 0001864141 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,772 Underlying: Common Shares · 5,885 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F5 · derivative.exercise_date: The RSUs were granted on November 10, 2021 and vest in three equal annual instalments beginning on November 10, 2022. F5 · derivative.expiration_date: The RSUs were granted on November 10, 2021 and vest in three equal annual instalments beginning on November 10, 2022. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 21:41 UTC | Zymeworks Inc. ZYME · Entity 4458 | SaleCommon Stock | 2,475 | $8.10 | $20,045.03 |
DisclosureSEC source: 0000899243-22-035813 · doc4.xml · nonDerivative · entry 2 Josephson Neil · CIK 0001864141 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,449 F2 · kind: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs. Pursuant to the terms of the applicable RSU grant agreement (the "Grant Agreement"), effective on the grant date of the RSUs, the Reporting Person adopted a 10b5-1 plan pursuant to which the Reporting Person elected to sell shares to cover tax withholding obligations and other applicable fees in accordance with the terms of the Grant Agreement. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.09 to $8.10, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 21:41 UTC | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionCommon Stock | 5,885 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-035813 · doc4.xml · nonDerivative · entry 1 Josephson Neil · CIK 0001864141 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on November 10, 2021. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 21:00 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionRestricted Stock Unit · Derivative | 5,885 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-035785 · doc4.xml · derivative · entry 3 Josephson Neil · CIK 0001864141 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,772 Underlying: Common Shares · 5,885 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F5 · derivative.exercise_date: The RSUs were granted on November 10, 2021 and vest in three equal annual instalments beginning on November 10, 2022. F5 · derivative.expiration_date: The RSUs were granted on November 10, 2021 and vest in three equal annual instalments beginning on November 10, 2022. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 21:00 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | SaleCommon Stock | 2,475 | $8.10 | $20,045.03 |
DisclosureSEC source: 0000899243-22-035785 · doc4.xml · nonDerivative · entry 2 Josephson Neil · CIK 0001864141 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,449 F2 · kind: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs. Pursuant to the terms of the applicable RSU grant agreement (the "Grant Agreement"), effective on the grant date of the RSUs, the Reporting Person adopted a 10b5-1 plan pursuant to which the Reporting Person elected to sell shares to cover tax withholding obligations and other applicable fees in accordance with the terms of the Grant Agreement. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.09 to $8.10, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 21:00 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionCommon Stock | 5,885 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-035785 · doc4.xml · nonDerivative · entry 1 Josephson Neil · CIK 0001864141 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on November 10, 2021. Read SEC document |
| November 10, 2022 Filed Dec 23, 2022 20:00 UTC Amendment | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionRestricted Stock Unit · Derivative | 5,885 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-039331 · doc4a.xml · derivative · entry 3 Josephson Neil · CIK 0001864141 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,772 Underlying: Common Shares · 5,885 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F5 · derivative.exercise_date: The RSUs were granted on November 10, 2021 and vest in three equal annual instalments beginning on November 10, 2022. F5 · derivative.expiration_date: The RSUs were granted on November 10, 2021 and vest in three equal annual instalments beginning on November 10, 2022. Read SEC document |
| November 10, 2022 Filed Dec 23, 2022 20:00 UTC Amendment | Zymeworks Inc. ZYME · Entity 4458 | SaleCommon Stock | 2,475 | $8.10 | $20,045.03 |
DisclosureSEC source: 0000899243-22-039331 · doc4a.xml · nonDerivative · entry 2 Josephson Neil · CIK 0001864141 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,449 F2 · kind: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs. Pursuant to the terms of the applicable RSU grant agreement (the "Grant Agreement"), effective on the grant date of the RSUs, the Reporting Person adopted a 10b5-1 plan pursuant to which the Reporting Person elected to sell shares to cover tax withholding obligations and other applicable fees in accordance with the terms of the Grant Agreement. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.09 to $8.10, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 10, 2022 Filed Dec 23, 2022 20:00 UTC Amendment | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionCommon Stock | 5,885 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-039331 · doc4a.xml · nonDerivative · entry 1 Josephson Neil · CIK 0001864141 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on November 10, 2021. Read SEC document |
| July 05, 2022 Filed Jul 5, 2022 21:00 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantCommon Shares | 1,525 | $4.51 | $6,877.75 |
DisclosureSEC source: 0000899243-22-025157 · doc4.xml · nonDerivative · entry 1 Josephson Neil · CIK 0001864141 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,039 F1 · kind: Shares purchased pursuant to the Issuer's Amended and Restated Employee Stock Purchase Plan (ESPP) for the ESPP purchase period January 1, 2022 through June 30, 2022. In accordance with the ESPP, these shares were purchased at a price equal to 85% the closing price of the Issuer's common shares on June 30, 2022. Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 21:00 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionRestricted Stock Unit · Derivative | 1,666 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-010794 · doc4.xml · derivative · entry 4 Josephson Neil · CIK 0001864141 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,334 Underlying: Common Shares · 1,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F5 · derivative.exercise_date: The RSUs were granted on March 10, 2021 and vest in three equal annual instalments beginning on March 10, 2022. F5 · derivative.expiration_date: The RSUs were granted on March 10, 2021 and vest in three equal annual instalments beginning on March 10, 2022. Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 21:00 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionRestricted Stock Unit · Derivative | 729 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-010794 · doc4.xml · derivative · entry 3 Josephson Neil · CIK 0001864141 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 730 Underlying: Common Shares · 729 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs were granted on March 10, 2020 and vest in three equal annual instalments beginning on March 10, 2021. F4 · derivative.expiration_date: The RSUs were granted on March 10, 2020 and vest in three equal annual instalments beginning on March 10, 2021. Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 21:00 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionCommon Shares | 1,666 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-010794 · doc4.xml · nonDerivative · entry 2 Josephson Neil · CIK 0001864141 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Represents common shares issued upon vesting of one third of the RSUs granted on March 10, 2021. Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 21:00 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | Exercise / conversionCommon Shares | 729 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-010794 · doc4.xml · nonDerivative · entry 1 Josephson Neil · CIK 0001864141 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,848 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents common shares issued upon vesting of one third of the restricted stock units ("RSUs") granted on March 10, 2020. Read SEC document |
| January 07, 2022 Filed Jan 7, 2022 21:30 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantCommon Shares | 65 | $13.94 | $906.10 |
DisclosureSEC source: 0000899243-22-001425 · doc4.xml · nonDerivative · entry 1 Josephson Neil · CIK 0001864141 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,119 F1 · kind: Shares purchased pursuant to the Issuer's Amended and Restated Employee Stock Purchase Plan (ESPP) for the ESPP purchase period July 1, 2021 through December 31, 2021. In accordance with the ESPP, these shares were purchased at a price equal to 85% the closing price of the Issuer's common shares on December 31, 2021. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:47 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | PurchaseCommon Shares | 3,600 | $14.28 | $51,408.00 |
DisclosureSEC source: 0000899243-22-001679 · doc4.xml · nonDerivative · entry 2 Josephson Neil · CIK 0001864141 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,119 Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:47 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | PurchaseCommon Shares | 1,400 | $14.27 | $19,978.00 |
DisclosureSEC source: 0000899243-22-001679 · doc4.xml · nonDerivative · entry 1 Josephson Neil · CIK 0001864141 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,519 Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 21:00 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantRestricted Stock Unit · Derivative | 17,657 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-044482 · doc4.xml · derivative · entry 2 Josephson Neil · CIK 0001864141 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,657 Underlying: Common Shares · 17,657 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on November 10, 2022. F3 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning on November 10, 2022. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 21:00 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantStock Option (Right to Buy) · Derivative | 105,943 | $0.00 Strike: $21.18 | $0.00 |
DisclosureSEC source: 0000899243-21-044482 · doc4.xml · derivative · entry 1 Josephson Neil · CIK 0001864141 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,943 Underlying: Common Shares · 105,943 shares Expires 2031-11-09 F1 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 20:00 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantCommon Shares | 461 | $29.49 | $13,594.89 |
DisclosureSEC source: 0000899243-21-027912 · doc4.xml · nonDerivative · entry 1 Josephson Neil · CIK 0001864141 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,054 F1 · kind: Shares purchased pursuant to the Issuer's Amended and Restated Employee Stock Purchase Plan (ESPP) for the ESPP purchase period January 1, 2021 through June 30, 2021. In accordance with the ESPP, these shares were purchased at a price equal to 85% the closing price of the Issuer's common shares on June 30, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.